DrugPatentWatch Database Preview
Horizon Pharma Company Profile
What is the competitive landscape for HORIZON PHARMA, and when can generic versions of HORIZON PHARMA drugs launch?
HORIZON PHARMA has four approved drugs.
There are sixteen US patents protecting HORIZON PHARMA drugs.
Summary for Horizon Pharma
| US Patents: | 16 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 4 |
| Patent Litigation for Horizon Pharma: | See patent lawsuits for Horizon Pharma |
Drugs and US Patents for Horizon Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Horizon Pharma | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-002 | Jul 26, 2012 | AB | RX | Yes | No | 9,504,699 | ➤ Sign Up | ➤ Sign Up | |||
| Horizon Pharma | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-001 | Jul 26, 2012 | AB | RX | Yes | No | 6,677,326 | ➤ Sign Up | Y | ➤ Sign Up | ||
| Horizon Pharma | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-003 | Jul 26, 2012 | AB | RX | Yes | Yes | 9,040,085 | ➤ Sign Up | ➤ Sign Up | |||
| Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-002 | Apr 30, 2013 | RX | Yes | Yes | 9,198,882*PED | ➤ Sign Up | Y | ➤ Sign Up | |||
| Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-002 | Apr 30, 2013 | RX | Yes | Yes | 9,925,157 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-002 | Apr 30, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Horizon Pharma | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-001 | Jul 26, 2012 | AB | RX | Yes | No | 6,488,960 | ➤ Sign Up | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Horizon Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Horizon Pharma Inc | BUPHENYL | sodium phenylbutyrate | POWDER;ORAL | 020573-001 | Apr 30, 1996 | 4,457,942 | ➤ Sign Up |
| Horizon Pharma Inc | BUPHENYL | sodium phenylbutyrate | TABLET;ORAL | 020572-001 | May 13, 1996 | 4,457,942 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for HORIZON PHARMA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 1 mg, 2 mg, and 5 mg | ➤ Subscribe | 2012-11-26 |
International Patents for Horizon Pharma Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Eurasian Patent Organization | 201690036 | ➤ Sign Up |
| Poland | 2049123 | ➤ Sign Up |
| Spain | 2400446 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2014204881 | ➤ Sign Up |
| Slovenia | 1631251 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 0054780 | ➤ Sign Up |
| Australia | 8789501 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Horizon Pharma Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 90062-5 | Sweden | ➤ Sign Up | PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516 |
| 90064-1 | Sweden | ➤ Sign Up | PRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516 |
| C0055 | France | ➤ Sign Up | PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220 |
| C/GB08/036 | United Kingdom | ➤ Sign Up | PRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425 |
| 666 | Luxembourg | ➤ Sign Up | PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119 |
| C0052 | France | ➤ Sign Up | PRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725 |
| C/GB98/030 | United Kingdom | ➤ Sign Up | PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
